A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer